New inhaler combo shows promise for Hard-to-Control asthma

NCT ID NCT02127866

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 06, 2026 · Updated 4 times

Summary

This study tested whether adding a third medicine (glycopyrrolate) to a standard asthma inhaler (Foster) helps people whose asthma is not well controlled. About 211 adults with uncontrolled asthma took part. The main goal was to see if the new combination improved lung function over 12 hours compared to the standard inhaler alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Chiesi Clinical Trial Site 0101

Rousse, 7002, Bulgaria
Chiesi Clinical Trial Site 0102

Sofia, 1407, Bulgaria
Chiesi Clinical Trial Site 0103

Stara Zagora, 6003, Bulgaria
Chiesi Clinical Trial Site 0104

Troyan Municipality, 5600, Bulgaria
Chiesi Clinical Trial Site 0105

Dupnitsa, 2600, Bulgaria
Chiesi Clinical Trial Site 0106

Sevlievo, 5400, Bulgaria
Chiesi Clinical Trial Site 0107

Sofia, 1233, Bulgaria
Chiesi Clinical Trial Site 0108

Sofia, 1336, Bulgaria
Chiesi Clinical Trial Site 0109

Sofia, 1432, Bulgaria
Chiesi Clinical Trial Site 0110

Sofia, 1431, Bulgaria
Chiesi Clinical Trial Site 0201

Leipzig, 04357, Germany
Chiesi Clinical Trial Site 0202

Magdeburg, 39112, Germany
Chiesi Clinical Trial Site 0203

Lübeck, 23552, Germany
Chiesi Clinical Trial Site 0204

Radebeul, 01445, Germany
Chiesi Clinical Trial Site 0206

Großhansdorf, 22927, Germany
Chiesi Clinical Trial Site 0207

Berlin, 12165, Germany
Chiesi Clinical Trial Site 0208

Berlin, 10787, Germany
Chiesi Clinical Trial Site 0210

Witten, 58452, Germany
Chiesi Clinical Trial Site 0301

Siófok, 8600, Hungary
Chiesi Clinical Trial Site 0302

Budapest, 1122, Hungary
Chiesi Clinical Trial Site 0303

Komárom, 2900, Hungary
Chiesi Clinical Trial Site 0304

Deszk, 6772, Hungary
Chiesi Clinical Trial Site 0305

Gödöllő, 2100, Hungary
Chiesi Clinical Trial Site 0306

Szarvas, 5540, Hungary
Chiesi Clinical Trial Site 0307

Balassagyarmat, 2660, Hungary
Chiesi Clinical Trial Site 0401

Pisa, 56124, Italy
Chiesi Clinical Trial Site 0402

Parma, 43125, Italy
Chiesi Clinical Trial Site 0403

Brescia, 25123, Italy
Chiesi Clinical Trial Site 0404

Verona, 37134, Italy
Chiesi Clinical Trial Site 0408

Trieste, 34149, Italy
Chiesi Clinical Trial Site 0501

Oświęcim, 32-600, Poland
Chiesi Clinical Trial Site 0502

Giżycko, 11-500, Poland
Chiesi Clinical Trial Site 0503

Ostróda, 14-100, Poland
Chiesi Clinical Trial Site 0504

Wroclaw, 51-162, Poland
Chiesi Clinical Trial Site 0505

Lodz, 90-141, Poland
Chiesi Clinical Trial Site 0506

Proszowice, 32-100, Poland
Chiesi Clinical Trial Site 0507

Gdansk, 80-847, Poland
Chiesi Clinical Trial Site 0508

Rzeszów, 35-241, Poland
Chiesi Clinical Trial Site 0509

Lodz, 90-153, Poland
Chiesi Clinical Trial Site 0510

Bialystok, 15-430, Poland
Chiesi Clinical Trial Site 0511

Krakow, 31-637, Poland
Chiesi Clinical Trial Site 0512

Lublin, 20-718, Poland
Chiesi Clinical Trial Site 0601

Manchester, M23 9QZ, United Kingdom
Chiesi Clinical Trial Site 0602

London, W1G 8HU, United Kingdom

Conditions

Explore the condition pages connected to this study.

ASTHMA